Mamta Garg

Leicester Royal Infirmary — United Kingdom

Medicine · Health Sciences

28h-index5.1kcitations155works13.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(90), Protein Degradation and Inhibitors(52), Myeloproliferative Neoplasms: Diagnosis and Treatment(26), Cancer Treatment and Pharmacology(23), Peptidase Inhibition and Analysis(23)

Publications154 total

Investigation and management of thrombocytosis without <scp> <i>JAK2</i> </scp> , <scp> <i>CALR</i> </scp> or <scp> <i>MPL</i> </scp> mutations: A British Society for Haematology Guideline
British Journal of Haematology·2025Open Access
Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study
Blood·2025
Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network
Blood·2025Open Access
Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
British Journal of Haematology·2025· 1 cited
A cross-sectional study about knowledge, attitude and practice regarding anemia among school going adolescent girls in Naila, Jaipur, Rajasthan
International Journal of Adolescent Medicine and Health·2025Open Access
Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
The Lancet Oncology·2025· 7 cited
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data
eJHaem·2025Open Access
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
The Lancet Oncology·2025· 11 citedOpen Access
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms
eJHaem·2025· 1 citedOpen Access
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
American Journal of Hematology·2025· 10 citedOpen Access
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Blood·2024· 11 cited
Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Blood·2024· 2 citedOpen Access
Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
Blood·2024· 1 citedOpen Access
Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
Blood·2024· 6 citedOpen Access
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
The Lancet Haematology·2024· 7 citedOpen Access
OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine·2024· 127 cited
Guideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology Guideline
British Journal of Haematology·2024· 5 citedOpen Access
Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline
British Journal of Haematology·2024· 13 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Meletios Α. Dimopoulos(16), Michèle Cavo(15), María‐Victoria Mateos(13), Kenshi Suzuki(13), Sebastian Grosicki(13), Martin Kaiser(11), Roger G. Owen(11), Roman Hájek(10), Graham Jackson(10), Matthew Jenner(10), Gordon Cook(10), Nigel H. Russell(10), Mark T. Drayson(10), Gareth J. Morgan(10), Anna Marina Liberati(9), Tomoaki Fujisaki(9), Philippe Moreau(9), Faith E. Davies(9), Stefan Knop(8), Chantal Doyen(8)